Why Trevi Therapeutics (TRVI) Is Advancing Today
With Trevi poised to soon announce data from a trial of its Haduvio drug as a treatment for refractory chronic cough (RCC), Stifel predicts that the readout will be positive.
Trevi Therapeutics Inc. (TRVI)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Viking Global Andreas Halvorsen | 4,400,000 | $18,128,000 | 0.05% | |
| 2. | Rubric Capital Management David Rosen | 4,205,129 | $17,325,131 | -17% | 0.22% |
| 3. | Point72 Asset Management Steve Cohen | 4,150,237 | $17,098,977 | 0.03% | |
| 4. | Vivo Capital Albert Cha And Frank Kung | 3,487,903 | $14,370,160 | +117% | 1.6% |
| 5. | Woodline Partners Michael Rockefeller And Karl Kroeker | 3,212,597 | $13,235,900 | +430% | 0.08% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $1.90 | 948,948 | Large Shareholder | 948,948 | 2022-04-11 | Filing | |
| $1.90 | 2,631,578 | Large Shareholder | 10,421,428 | 2022-04-11 | Filing | |
| $1.90 | 948,948 | Large Shareholder | 948,948 | 2022-04-11 | Filing | |
| $1.90 | 2,631,578 | Large Shareholder | 10,421,428 | 2022-04-11 | Filing | |
| $1.90 | 948,948 | Large Shareholder | 948,948 | 2022-04-11 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $3.04 | 1,840 | 213,313 | 2024-09-09 | Filing | ||
| $3.03 | 4,219 | 213,313 | 2024-09-06 | Filing | ||
| $3.11 | 40,277 | 213,313 | 2024-09-05 | Filing | ||
| $3.02 | 10,981 | 213,313 | 2024-09-04 | Filing | ||
| $3.02 | 3,863 | 213,313 | 2024-09-03 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 11,370,376 | $48,845,949 | 2.75% | |
| 2. | 10,664,774 | $43,938,869 | 1.82% | |
| 3. | 3,928,462 | $16,185,263 | 0% | |
| 4. | 3,509,213 | $14,457,958 | 0% | |
| 5. | 2,001,048 | $8,244,318 | 4.45% |
News See All
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Q3 2024 Earnings Call Transcript
Operator: Good afternoon, and welcome to the Trevi Therapeutics Third Quarter 2024 Earnings Conference Call. At this time, all participants will be in listen-only mode.
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Q2 2024 Earnings Call Transcript
Operator: Good afternoon. And welcome to the Trevi Therapeutics Second Quarter 2024 Earnings Conference Call. At this time, all participants will be in a listen-only mode.
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Q1 2024 Earnings Call Transcript
Operator: Good afternoon, and welcome to the Trevi Therapeutics First Quarter 2024 Earnings Conference Call. At this time, all participants will be in a listen-only mode.
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Q4 2023 Earnings Call Transcript
Trevi Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.08, expectations were $-0.1.
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Q3 2023 Earnings Call Transcript
Operator: Good afternoon and welcome to the Trevi Therapeutics Q3 2023 Earnings Conference Call. At this time all participants will be in a listen-only mode.
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Q2 2023 Earnings Call Transcript
Operator: Good afternoon and welcome to the Trevi Therapeutics’ Second Quarter 2023 Earnings Conference Call. [Operator Instructions] Please note this event is being recorded.
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Q1 2023 Earnings Call Transcript
Operator: Good afternoon and welcome to the Trevi Therapeutics’ Q1 2023 Earnings Conference Call. [Operator Instructions] Please note this event is being recorded.
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Q4 2022 Earnings Call Transcript
Operator: Good afternoon and welcome to the Trevi Therapeutics Q4 and Year-End 2022 Earnings Conference Call. Please note this event is being recorded.
Billionaire Hedge Funds
